<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Only a few reports have suggested the efficacy of adjuvant chemotherapy including <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> based regimens following surgical resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> from <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Since an administration of mFOLFOX6 was approved to medical insurance for advanced <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> as adjuvant chemotherapy, we applied mFOLFOX6 treatment (6 to 12 courses) to the patients who underwent curative resection of colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The subjects were 14 patients who underwent curative resection for synchronous or metachronous colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> and received mFOLFOX6 treatment postoperatively from January 2006 to January 2011 </plain></SENT>
<SENT sid="3" pm="."><plain>We retrospectively analyzed the patient's characteristics, relapse free survival, overall survival, and adverse events in these patients </plain></SENT>
<SENT sid="4" pm="."><plain>Synchronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> was found in 5 patients, while metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> was observed in 9 patients </plain></SENT>
<SENT sid="5" pm="."><plain>There were no significant differences between these patients in terms of clinical characteristics, the relapse free survival and overall survival </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had some adverse events including bone-marrow suppression and <z:hpo ids='HP_0002014'>diarrhea</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Especially, grade 3 or higher bone-marrow suppression were recognized in 6 patients (42.8%) </plain></SENT>
<SENT sid="8" pm="."><plain>Neurologic toxicity (â‰¤ grade 2) was observed in 10 patients (71.4%) </plain></SENT>
<SENT sid="9" pm="."><plain>Adjuvant chemotherapy with mFOLFOX6 treatment following surgical resection of synchronous or metachronous <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> was safely administered </plain></SENT>
<SENT sid="10" pm="."><plain>We will further examine the benefit of mFOLFOX6 treatment for the patients who undergo a surgical resection of <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> in the future </plain></SENT>
</text></document>